Navigation Links
Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
Date:6/12/2008

and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of forward-looking terminology such as "anticipate," "could," "may," "will," or similar expressions, or by express or implied statements with respect to the company's clinical development programs in HIV, or any potential pipeline candidates for the treatment of HIV, including any expressed or implied statement regarding the efficacy and safety of IDX899 and any future clinical trials involving IDX899. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, pre-clinical studies and/or clinical trials, including additional data relating to the ongoing pre-clinical studies and/or clinical trials evaluating its product candidates, including IDX899; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG; changes in the company's business plan or objectiv
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
3. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
6. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
7. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
8. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
9. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
10. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
11. European Unions CHMP Issues Positive Opinion on Sugammadex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... AMSTERDAM, December 16 Today, Avantium ... Executive Officer of its pharmaceutical,business. Gunnar Staaf ... and Eli Lilly & Company, in a ... is an important step in Avantium,s plan ... to create a,stand-alone pharmaceutical company based on ...
(Date:12/16/2009)... Senate Vote Against Lower Prescription Drug Prices ... Senate on Tuesday night rejected an amendment to ... would help make prescription drugs more affordable by ... lower priced drugs from abroad. The bipartisan ... Dorgan, Snowe, McCain, Grassley and Stabenow, would have ...
(Date:12/16/2009)... Calif., Dec. 16 Frost & ... Bujnoch, looks forward to speaking at the ... taking place on January 9, 2010 in ... the emerging market of consumer-based digital health ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, Bujnoch ...
Breaking Medicine Technology:Avantium Appoints Gunnar Staaf as CEO Pharma 2AARP Illinois Key Vote News Alert 2Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit 2Optimization and Scale up of a Hydrodynamically Limited Anti Solvent Crystallization Process 3A From Lab to Plant 13541 1Optimization and Scale up of a Hydrodynamically Limited Anti Solvent Crystallization Process 3A From Lab to Plant 13541 2TrueVision Teams with Ophthalmologists to Help Cure World Blindness for Treatable Cataracts Debut of 3D Training Video for Manual Small Incision C 54393 1TrueVision Teams with Ophthalmologists to Help Cure World Blindness for Treatable Cataracts Debut of 3D Training Video for Manual Small Incision C 54393 2TrueVision Teams with Ophthalmologists to Help Cure World Blindness for Treatable Cataracts Debut of 3D Training Video for Manual Small Incision C 54393 3TrueVision Teams with Ophthalmologists to Help Cure World Blindness for Treatable Cataracts Debut of 3D Training Video for Manual Small Incision C 54393 4Medco Health Solutions United Drug Announce U K Homecare Pharmacy Joint Venture Serving Patients with Chronic and Complex Health Conditions 3B Innov 54388 1Medco Health Solutions United Drug Announce U K Homecare Pharmacy Joint Venture Serving Patients with Chronic and Complex Health Conditions 3B Innov 54388 2Medco Health Solutions United Drug Announce U K Homecare Pharmacy Joint Venture Serving Patients with Chronic and Complex Health Conditions 3B Innov 54388 3
... Product Candidate in Clinical Trials, SEATTLE, Sept. ... enrolling patients in a Phase 1/Phase 2 study ... use during,ophthalmologic surgery. At least 60 patients undergoing ... enrollment in the,study., "With the initiation of ...
... 8 FluoroPharma, Inc. announced today that,Dr. ... Advisor,will report on two preclinical studies demonstrating ... molecular imaging agents for detection,of Alzheimer,s disease ... Molecular,Imaging Congress, in Nice, France on September ...
Other Medicine Technology:Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302 2FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents 2FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents 3
(Date:12/16/2009)... 16, 2009 -- Every year in the United States, ... patients die of the disease, making it the second ... lung cancer. , As researchers and clinicians fervently look ... generating thousands of studies producing more and more promising ... cancer and genetics at Case Western Reserve University School ...
(Date:12/16/2009)... WASHINGTON, Dec. 16 Losing has never felt ... knows maintaining his healthy new lifestyle means continuing to ... Drinking fat free milk is one healthy choice that ... a simple step everyone can take. Every glass of ... muscle, potassium to help maintain normal blood pressure, and ...
(Date:12/16/2009)... most widely used human embryonic stem cell lines lack ... that must be addressed to ensure that all sectors ... a University of Michigan research team. ,, In the ... analyzed 47 embryonic stem cell lines, including most of ... scientists determined the genetic ancestry of each line and ...
(Date:12/16/2009)... long-term goal, researchers say , , WEDNESDAY, Dec. 16 ... predict whether a patient will suffer a second stroke ... is an important new tool because studies have shown ... a first stroke are more likely to die or ... Hospital and Harvard Medical School, said in an American ...
(Date:12/16/2009)... Wellcome Trust Sanger Institute announce the first comprehensive analyses ... by mutations in the DNA of cancer cells which ... a malignant melanoma and a lung cancer, reveal for ... genomes of two cancers. , Lung cancer causes around ... associated with smoking. The number of mutations found suggest ...
Breaking Medicine News(10 mins):Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6
... with a second newer agent has proven to be effective ... be published in its July 7th special HIV/AIDS issue. ... 18 nations and more than 30 centers in the United ... resistant HIV the potential of receiving two investigational new drugs ...
... police inquiries as focus shifted to Australia. ... attacks in UK raided two hospitals in Western Australia and ... Indian. ,However, WA Premier Alan Carpenter said he ... ,"There is nothing that has been presented to ...
... a blood-clotting protein found in circulating blood, has been ... neuronal cells , a process that is necessary for ... ,The findings by researchers at the University ... explain why the human body is unable to repair ...
... Didrick of Naples, Florida, has come up with a fascinating ... in 150 persons do lose a digit , it is ... because it has no batteries, electronics, servos or actuators. Instead, ... the surviving part of the wearer's finger, curls a set ...
... a way to produce blood vessels by engineering tissues ... ,Researchers at the University at Buffalo Department of Chemical ... an excellent source of adult stem cells, containing smooth ... cells can be used in regenerative medicine for cardiovascular ...
... conducted by Henley Management College and the University of Milan ... age of 65 is significantly higher than it is ... study was to make the first step in the modelling ... prescribing funds. ,The research found that the mean ...
Other Medicine News:Health News:New Drugs Show Promise in Fighting Drug-Resistant HIV 2Health News:New Drugs Show Promise in Fighting Drug-Resistant HIV 3Health News:More Indian Doctors Questioned in Australia as UK Terror Plot Inquiry Widens 2Health News:Fibrinogen may Inhibit Spinal Cord Regeneration 2Health News:A Mechanical Prosthetic Close to the Real Thing 2Health News:New Blood Vessels can Be Created from Bone Marrow Stem Cells: Study 2
... The Volk G-1 trabeculum provides the highest magnification ... for viewing and treating the trabecular meshwork. ... the anterior chamber angle while the central portion ... the posterior pole for signs of glaucoma and ...
... Volks Disposable SSV® Vitrectomy Lenses are a ... to enable a view of a particular region ... contact lens element weighs less than 1 gram ... with the typical shape of a human cornea. ...
... 30° Prism are designed for ... recommended for tractional retinal detachments ... retinal detachment. They can be ... other midperipheral laser applications. Direct ...
... The 30° Prism is ... pathologies and are recommended ... (PDR, BRVO etc.) and ... can be used for ...
Medicine Products: